Loading…
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (14)
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020 HR 7956 - Critical Medical Infrastructure Right-to-Repair Act of 2020 S 4473 - Critical Medical Infrastructure Right-to-Repair Act of 2020 Health Care Cybersecurity
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2020 · third_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET; GDUFA, PDUFA COVID Relief, Medical Device Servicing; Medical Device Servicing, Focused Ultrasound; Medical Device Servicing
Client expense: $360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · third_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · second_quarter · Health Issues
3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of Non-oncologic PET; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of Non-oncologic PET Provider relief; Provider relief; Provider relief, TRICARE DBT coverage
Client expense: $3,000,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · second_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $3,000,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
| Democratic |
| IL |
| Bonnie Watson Coleman | Democratic | NJ |
| Darren Soto | Democratic | FL |
| David Loebsack | Democratic | IA |
| Dean Phillips | Democratic | MN |
| Donald M. Payne, Jr. | Democratic | NJ |
| Elissa Slotkin | Democratic | MI |
| George Holding | Republican | NC |
| Gregory F. Murphy | Republican | NC |
| Guy Reschenthaler | Republican | PA |
| Harley Rouda | Democratic | CA |
| Jackie Walorski | Republican | IN |
| James P. McGovern | Democratic | MA |
| John H. Rutherford | Republican | FL |
| Lisa Blunt Rochester | Democratic | DE |
| Raja Krishnamoorthi | Democratic | IL |
| Seth Moulton | Democratic | MA |
| Susan W. Brooks | Republican | IN |
| Ted Lieu | Democratic | CA |
| Terri A. Sewell | Democratic | AL |
| Tim Burchett | Republican | TN |
2020 · fourth_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020 HR 7956 - Critical Medical Infrastructure Right-to-Repair Act of 2020 S 4473 - Critical Medical Infrastructure Right-to-Repair Act of 2020 Health Care Cybersecurity
Client expense: $940,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Health Issues
Coverage and Payment for Nuclear Medicine generally; HR 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 specifically. Meet with Defense Logistics Agency to discuss progress relating to government contracts for Members involving medical device contracts Planning for meeting with Defense Health Agency and the National Acquisitions Center/ Veterans' Affairs regarding medical device government contracts Questions on the implementation at the Defense Health Agency of the Cybersecurity maturity model certification and general agenda setting for Defense Health Agency and the VA/National Acquisition Center
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Health Issues
Coverage and Payment for Nuclear Medicine generally; HR 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 specifically. Medical Device Servicing, MDUFA, DLA Procurement Policies; Focused Ultrasound, Provider E/M Policies; The Critical Medical Infrastructure Right-to-Repair Act of 2020; Meet with Defense Logistics Agency to discuss progress relating to government contracts for Members involving medical device contracts Planning for meeting with Defense Health Agency and the National Acquisitions Center/ Veterans' Affairs regarding medical device government contracts Questions on the implementation at the Defense Health Agency of the Cybersecurity maturity model certification and general agenda setting for Defense Health Agency and the VA/National Acquisition Center
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $210,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · third_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET; GDUFA, PDUFA COVID Relief, Medical Device Servicing; Medical Device Servicing, Focused Ultrasound; Medical Device Servicing
Client expense: $210,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · second_quarter · Health Issues
3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of Non-oncologic PET; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of Non-oncologic PET Provider relief; Provider relief; Provider relief, TRICARE DBT coverage
Client expense: $146,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · second_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $146,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · first_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $670,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020 HR 7956 - Critical Medical Infrastructure Right-to-Repair Act of 2020 S 4473 - Critical Medical Infrastructure Right-to-Repair Act of 2020 Health Care Cybersecurity
Client expense: $940,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2020 · second_quarter · Health Issues
Medical Device Servicing HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 Defense Production Act for Ventilators COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade
Client expense: $1,190,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2020 · first_quarter · Health Issues
Medical Device Servicing HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 Defense Production Act for Ventilators COVID-19 response
Client expense: $1,690,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2020 · third_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Coverage and Payment for Nuclear Medicine generally; HR 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 specifically. Medical Device Servicing, MDUFA, DLA Procurement Policies; Focused Ultrasound, Provider E/M Policies; The Critical Medical Infrastructure Right-to-Repair Act of 2020; Meet with Defense Logistics Agency to discuss progress relating to government contracts for Members involving medical device contracts Planning for meeting with Defense Health Agency and the National Acquisitions Center/ Veterans' Affairs regarding medical device government contracts Questions on the implementation at the Defense Health Agency of the Cybersecurity maturity model certification and general agenda setting for Defense Health Agency and the VA/National Acquisition Center
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $950,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
Medicare Part A, B and D AMP Cap H.R 3 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1046/S.377 - Medicare Negotiation and Competitive Licensing Act of 2019 Innovative pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Drug Pricing Outcomes Based Contracts/value based arrangements Medicaid H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R.448 - Medicare Drug Price Negotiation Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.107 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R.4455 - BIOSIM Act H.R.4619 - Pharmaceutical Rebates for Excessive Pricing Above Inflation Act HR. 3772 - The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 HR. 4597 - Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 S.3466 - ACCESS for Biosimilars Act of 2020 HR. 6179 - Increasing Access to Biosimilars Act of 2020 HR. 4629 - Star Rating for Biosimilars Act S. 3129 - Lower Costs, More Cures Act of 2019 S. 3384 - Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 S. 3457 - Preserving Patient Access to Home Infusion Act H.R.5741 - Strengthening Innovation in Medicare and Medicaid Act Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Transparency policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08) Proposed Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans (CMS-9916-P) Reimbursement for cell therapy products S. 3353/H.R. 5534 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act Patient Cost-Sharing and Smoothing S. 4134 - Increasing Access to Biosimilars Act of 2020 S. 102 - Prescription Drug Price Relief Act of 2019 CMS Proposed Rule: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) or Drugs Covered in Medicaid, Revising Medicaid Rebate and Third Party Liability (TPL) Requirements (CMS-2482-P) H.R. 8624 - Protecting Access to Innovation During COVID-19 Act H.R. 8702 - Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020 S. 1895 - Lower Health Care Costs Act S. 4199 - Prescription Drug Pricing Reduction Act of 2020 S. 4274 - Legalizing Drug Discounts for Seniors Act of 2020 Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Medicare prescription drug payments cards and related issues ASP reporting policy issues Non-covered drugs policy issues Drug wastage rebates policy issues
Client expense: $660,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
S.2543 - Prescription Drug Pricing Reduction Act of 2019 HR 1499: Protecting Consumer Access to Generic Drugs Act Cell, gene and radioligand therapies 340B Drug Discount Program Drug Importation Outcomes based Contracting/Value based arrangements Orphan Drugs Medicaid Payment Reform AMP Cap S 1895 - Lower Health Care Costs Act HR 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.478 - Safe and Affordable Drugs from Canada Act of 2019 H.R.2011 - Protecting Access to Biosimilars Act of 2019 H.R.2296 - FAIR Drug Pricing Act of 2019 S.61 - Safe and Affordable Drugs from Canada Act of 2019 S.1140 - Protecting Access to Biosimilars Act of 2019 S.1384 - Prescription Drug Rebate Reform Act of 2019 S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 S.1227 - Prescription Pricing for the People Act of 2019 H.R.447 - Affordable and Safe Prescription Drug Importation Act H.R.1922 - Restoring Access to Medication Act of 2019 H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes H.R.5304 - PBM Transparency in Prescription Drug Costs Act S.97 - Affordable and Safe Prescription Drug Importation Act S.657 - A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits Transparency policy issues Drug cost and pricing policy issues PDUFA, BSUFA, GDUFA Drug vial size policy issues Pharmaceutical supply chain H.R. 4710 - Pharmaceutical Independence Long-Term Readiness Reform Act S. 3635 - Protecting our Pharmaceutical Supply Chain from China Act of 2020 S. 3538 - Strengthening Americas Supply Chain and Medical Security Act H.R. 6431 - Made in America Emergency Preparedness Act HR 6080 - Prevent Drug Shortages Act S. 3432 - Securing Americas Medicine Cabinet Act of 2020 H.R. 6670 - Prescription for American Drug Independence Act of 2020 H.R. 6930 - MADE in America Act HR 4439 - Creating Hope Reauthorization Act Pharmaceutical quality COVID 19 H.R 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act H.R. 748 and S. 3548 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act) H.R. 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 S. 3370 - Coronavirus Vaccine Act CARES Act, Pub. L. 116-136 H.R. 6080 - Preventing Drug Shortages Act Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Diversity in Clinical Trials FY 2021 Labor-HHS Appropriations Cures 2.0 Energy and Commerce RFI Part B Home Infusion Notice of Benefit Payment Parameters (NBPP) Priority Review Voucher (PRV) H.R. 4400 - The Advancing Education on Biosimilars Act of 2019 Vaccines Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) - Provisions on Part B and D, Most Favored Nation, and other issues Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020) Executive Order 13938, Increasing Drug Importation to Lower Prices for American Patients (July 24, 2020) Medicaid Generics Penalty fix HR 8337 - Continuing Appropriations Act, 2021 and Other Extensions Act H.R.2374 - Stop STALLING Act H.R. 5239 - Prescription Drug Price Reporting Act H.R. 6258 - Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 H.R. 6390 - To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak H.R. 6410 - To direct the President to use authority under the Defense Production Act of 1950 to ensure an adequate supply equipment necessary for limiting the spread of COVID-19 H.R. 6395/S. 4049 - National Defense Authorization Act for Fiscal Year 2021 HHS PREP Act declaration relating to COVID-19 Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Expanded access policy issues FDA modernization policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues FDA mandatory recall authority policy issues COVID-19 policy issues Transparency Issues Policy Issue H.R. 2477 - Beneficiary Enrollment Notification and the Eligibility Simplification (BENES) Act of 2019 H.R. 6800 - Heroes Act
Client expense: $660,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Energy/Nuclear
American Medical Isotopes Production Act of 2012: Section 2: Improving the Reliability of Domestic Medical Isotope Supply- implementation; H.R.3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client expense: $710,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
S.2772 - Medicare Mental Health Access Act H.R.3772- Medicare Diagnostic Radiopharmaceutical Payment Equality Act of 2019 H.R. 7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 Medicaid non-emergency medical transportation (NEMT) S.475 - RxCAP Act of 2019 H.R. 945/S. 286, the Mental Health Access Improvement Act of 2019 Support of an out-of-pocket spending cap for Medicare Part D Support for Value Based Arrangements in Medicare and Medicaid
Client expense: $18,500 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2020 · fourth_quarter · Health Issues
Issues regarding the reimbursement of radiopharmaceuticals H.R. 3772
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues regarding the reimbursement of radiopharmaceuticals H.R. 3772
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020 HR 7956 - Critical Medical Infrastructure Right-to-Repair Act of 2020 S 4473 - Critical Medical Infrastructure Right-to-Repair Act of 2020 Health Care Cybersecurity
Client expense: $940,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Science/Technology
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issues related to appropriate payment legislation for diagnostic radiopharmaceuticals; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
To gain support for adequate Medicare reimbursement for diagnostic radiopharmaceuticals; H.R. 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
To gain support for adequate Medicare reimbursement for diagnostic radiopharmaceuticals; H.R. 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Advocacy on outpatient package payment and H.R. 3772
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
HR 3772 Medicare Diagnostic Radiopharmaceutical Equity Act; and Onshoring Pharmaceutical Manufacturing
Client expense: $30,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.3772- Medicare Diagnostic Radiopharmaceutical Payment Equality Act of 2019 H.R. 7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 Medicaid non-emergency medical transportation (NEMT) S.475 - RxCAP Act of 2019 H.R. 945/S. 286, the Mental Health Access Improvement Act of 2019 Support of an out-of-pocket spending cap for Medicare Part D Support for Value Based Arrangements in Medicare and Medicaid
Client expense: $18,400 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2020 · third_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET.; HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; Coverage of non-oncologic PET; GDUFA, PDUFA COVID Relief, Medical Device Servicing; Medical Device Servicing, Focused Ultrasound; Medical Device Servicing
Client expense: $210,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · third_quarter · Medicare/Medicaid
Radiopharmaceutical Payment Equity Act of 2019; HR 3772 - Medicare Diagnostic
Client expense: $210,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2020 · third_quarter · Science/Technology
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medical/Disease Research/Clinical Labs
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Administrative and legislative monitoring and outreach related to Alzheimers Disease research funding. Administrative and legislative monitoring and outreach related to pass-through payments for clinical trials. H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Energy/Nuclear
American Medical Isotopes Production Act of 2012: Section 2: Improving the Reliability of Domestic Medical Isotope Supply- implementation; H.R.3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client expense: $560,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $1,060,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · third_quarter · Health Issues
HR 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. S 2543 - Prescription Drug Pricing Reduction Act of 2019. S 551 - Recovering Excessive Funds for Unused and Needless Drugs Act of 2019 HR 5238 - Better and Robust Screening Today Act S 2955 - Better and Robust Screening Today Act HR 3224 Deborah Sampson Act S 3343 - Medical Supply Chain Security Act S 3468 - Preventing Essential Medical Device Shortages Act of 2020 Defense Production Act for Ventilators COVID-19 response Energy and Water Appropriations Health and Human Services Appropriations Healthcare trade HR 7574 - Strengthening America's Strategic National Stockpile Act of 2020 HR 7956 - Critical Medical Infrastructure Right-to-Repair Act of 2020 S 4473 - Critical Medical Infrastructure Right-to-Repair Act of 2020
Client expense: $850,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
S.2543 - Prescription Drug Pricing Reduction Act of 2019 HR 1499: Protecting Consumer Access to Generic Drugs Act Cell, gene and radioligand therapies 340B Drug Discount Program Drug Importation Outcomes based Contracting/Value based arrangements Orphan Drugs Medicaid Payment Reform AMP Cap S 1895 - Lower Health Care Costs Act HR 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.478 - Safe and Affordable Drugs from Canada Act of 2019 H.R.2011 - Protecting Access to Biosimilars Act of 2019 H.R.2296 - FAIR Drug Pricing Act of 2019 S.61 - Safe and Affordable Drugs from Canada Act of 2019 S.1140 - Protecting Access to Biosimilars Act of 2019 S.1384 - Prescription Drug Rebate Reform Act of 2019 S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 S.1227 - Prescription Pricing for the People Act of 2019 H.R.447 - Affordable and Safe Prescription Drug Importation Act H.R.1922 - Restoring Access to Medication Act of 2019 H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes H.R.5304 - PBM Transparency in Prescription Drug Costs Act S.97 - Affordable and Safe Prescription Drug Importation Act S.657 - A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits Transparency policy issues Drug cost and pricing policy issues PDUFA, BSUFA, GDUFA Drug vial size policy issues Pharmaceutical supply chain HR 6800 - Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) H.R. 4710 - Pharmaceutical Independence Long-Term Readiness Reform Act S. 3635 - Protecting our Pharmaceutical Supply Chain from China Act of 2020 S. 3538 - Strengthening Americas Supply Chain and Medical Security Act H.R. 6431 - Made in America Emergency Preparedness Act HR 6080 - Prevent Drug Shortages Act S. 3432 - Securing Americas Medicine Cabinet Act of 2020 H.R. 6670 - Prescription for American Drug Independence Act of 2020 H.R. 6930 - MADE in America Act HR 4439 - Creating Hope Reauthorization Act Pharmaceutical quality COVID 19 H.R 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act H.R. 748 and S. 3548 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act) H.R. 3772 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 S. 3370 - Coronavirus Vaccine Act S. 3548 - CARES Act H.R. 6080 - Preventing Drug Shortages Act Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Diversity in Clinical Trials FY 2021 Labor-HHS Appropriations Cures 2.0 Energy and Commerce RFI Part B Home Infusion Notice of Benefit Payment Parameters (NBPP) Priority Review Voucher (PRV) H.R. 4400 - The Advancing Education on Biosimilars Act of 2019 Vaccines Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) - Provisions on Part B and D, Most Favored Nation, and other issues Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020) Executive Order 13938, Increasing Drug Importation to Lower Prices for American Patients (July 24, 2020) Medicaid Generics Penalty fix HR 8337 - Continuing Appropriations Act, 2021 and Other Extensions Act
Client expense: $1,190,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
Medicare Part A, B and D AMP Cap H.R 3 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1046/S.377 - Medicare Negotiation and Competitive Licensing Act of 2019 Innovative pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Drug Pricing Outcomes Based Contracts/value based arrangements Medicaid H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R.448 - Medicare Drug Price Negotiation Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.107 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R.4455 - BIOSIM Act H.R.4619 - Pharmaceutical Rebates for Excessive Pricing Above Inflation Act HR. 3772 - The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 HR. 4597 - Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 S.3466 - ACCESS for Biosimilars Act of 2020 HR. 6179 - Increasing Access to Biosimilars Act of 2020 HR. 4629 - Star Rating for Biosimilars Act S. 3129 - Lower Costs, More Cures Act of 2019 S. 3384 - Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 S. 3457 - Preserving Patient Access to Home Infusion Act H.R.5741 - Strengthening Innovation in Medicare and Medicaid Act Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Transparency policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08) Proposed Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans (CMS-9916-P) Reimbursement for cell therapy products S. 3353/H.R. 5534 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act Patient Cost-Sharing and Smoothing S. 4134 - Increasing Access to Biosimilars Act of 2020 S. 102 - Prescription Drug Price Relief Act of 2019 CMS Proposed Rule: Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) or Drugs Covered in Medicaid, Revising Medicaid Rebate and Third Party Liability (TPL) Requirements (CMS-2482-P)
Client expense: $1,190,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2020 · third_quarter · Medicare/Medicaid
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Medicare reimbursement of radiopharmaceuticals and nuclear medicine. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772). Medicare reimbursement of cardiac PET scans.
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Client expense: $1,150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE